Drug intelligence / Profile preview

cisplatin + cyclophosphamide + mitomycin

Development stage: Unknown
Lead developer: Michigan State University
Modality: Small Molecules
Administration: Intravenous

Overview

This is a combination chemotherapy regimen consisting of three cytotoxic agents: cisplatin, cyclophosphamide, and mitomycin. The combination has been studied primarily for treating advanced non-small-cell lung cancer and ovarian cancer. In clinical trials for non-small-cell lung cancer, this regimen has demonstrated a survival advantage over supportive care alone[1]. The typical dosing regimen includes cisplatin (75 mg/m²), cyclophosphamide (400 mg/m²), and mitomycin (10 mg/m²) administered intravenously at 3-week intervals[1].

Other names: cisplatin-cyclophosphamide-mitomycin combination chemotherapy

Targets

DNA

Beyond the preview

Go deeper on cisplatin + cyclophosphamide + mitomycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + cyclophosphamide + mitomycin.

Explore the full profile